A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 26 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Oct 2014 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016, as reported by ClinicalTrials.gov.